EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway

Adrish Sen, Salmaan Khan, Stefano Rossetti iD, Aaron Broege, Ian MacNeil, Ann DeLaForest, Jhomary Molden, Laura Davis, Charles Iversrud, Megan Seibel, Ross Kopher, Stephen Schulz und 1 weitere

Molecular Oncology · 2025-01 · 19 (1) · 225-247

DOI: 10.1002/1878-0261.13703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 02.08.2024. Verfasst von Adrish Sen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Celcuity, Inc., Minneapolis, MN, USA. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, MTOR Inhibitors, Signal Transduction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic castration‐resistant prostate cancer (mCRPC) is characterized by loss of androgen receptor (AR) sensitivity and oncogenic activation of the PI3K/AKT/mTOR (PAM) pathway. Loss of the PI3K regulator PTEN is frequent during prostate cancer (PC) initiation, progression, and therapeutic resistance. Co‐targeting the PAM/AR pathways is a promising mCRPC treatment strategy but is hampered by reciprocal negative feedback inhibition or feedback relief. Most PAM inhibitors selectively spare (or weakly inhibit) one or more key nodes of the PAM pathway, potentiating drug resistance depending on the PAM pathway mutation status of patients. We posited that gedatolisib, a uniformly potent inhibitor of all class I PI3K isoforms, as well as mTORC1 and mTORC2, would be more effective than inhibitors targeting single PAM pathway nodes in PC cells. Using a combination of functional and metabolic assays, we evaluated a panel of PC cell lines with different PTEN / PIK3CA status for their sensitivity to multi‐node PAM inhibitors (PI3K/mTOR: gedatolisib, samotolisib) and single‐node PAM inhibitors (PI3Kα: alpelisib; AKT: capivasertib; mTOR: everolimus). Gedatolisib induced anti‐proliferative and cytotoxic effects with greater potency and efficacy relative to the other PAM inhibitors, independent of PTEN / PIK3CA status. The superior effects of gedatolisib were likely associated with more effective inhibition of critical PAM‐controlled cell functions, including cell cycle, survival, protein synthesis, oxygen consumption rate, and glycolysis. Our results indicate that potent and simultaneous blockade of all class I PI3K isoforms, mTORC1, and mTORC2 could circumvent PTEN‐dependent resistance. Gedatolisib, as a single agent and in combination with other therapies, reported promising preliminary efficacy and safety in various solid tumor types. Gedatolisib is currently being evaluated in a Phase 1/2 clinical trial in combination with darolutamide in patients with mCRPC previously treated with an AR inhibitor, and in a Phase 3 clinical trial in combination with palbociclib and fulvestrant in patients with HR+/HER2− advanced breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMTOR InhibitorsSignal TransductionPhosphoinositide-3 Kinase InhibitorsHumansMaleCell Line, TumorPhosphatidylinositol 3-KinasesMorpholinesCell ProliferationProstatic NeoplasmsPyrimidinesTriazines

Stichwörter der Autor:innen

PI3K/AKT/mTOR pathwaygedatolisibinhibitorsprostate cancer

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMTOR InhibitorsgedatolisibPhosphoinositide-3 Kinase InhibitorsPhosphatidylinositol 3-KinasesMTOR protein, humanMorpholinesPyrimidinesTriazines

Autor:innen und Institutionen

  • Celcuity, Inc., Minneapolis, MN, USA.

ORCID-Profile: Stefano Rossetti, Lance Laing

Zitieren

APA

Sen, A., Khan, S., Rossetti, S., Broege, A., MacNeil, I., DeLaForest, A., Molden, J., Davis, L., Iversrud, C., Seibel, M., Kopher, R., Schulz, S., & Laing, L. (2025). Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway. Molecular Oncology, 19(1), 225-247. https://doi.org/10.1002/1878-0261.13703

Vancouver

Sen A, Khan S, Rossetti S, Broege A, MacNeil I, DeLaForest A, et al. Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway. Molecular Oncology. 2025;19(1):225-247. doi:10.1002/1878-0261.13703

BibTeX
@article{Sen2025,
  author = {Sen, Adrish and Khan, Salmaan and Rossetti, Stefano and Broege, Aaron and MacNeil, Ian and DeLaForest, Ann and Molden, Jhomary and Davis, Laura and Iversrud, Charles and Seibel, Megan and Kopher, Ross and Schulz, Stephen and Laing, Lance},
  title = {Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway},
  journal = {Molecular Oncology},
  year = {2025},
  volume = {19},
  number = {1},
  pages = {225--247},
  doi = {10.1002/1878-0261.13703}
}
Kostenlos starten →